82
R.K. Rath et al. / Journal of Organometallic Chemistry 633 (2001) 79–84
used as such. Elemental analysis was performed on a
140.93, 142.28 (C3–6,8–12), 156.09, 162.91 (C2,7), 170.74
(C1) (L2 ligand).
1
Perkin–Elmer 2400 CHN analyzer. The H- and 13C–
{1H}-NMR spectra were recorded on Bruker 200 MHz
and Bruker AMX 400 (carbon channel 100.6 MHz)
spectrometers using Me4Si as the standard. Visible elec-
tronic spectra were obtained from a Hitachi U-3400
spectrophotometer.
4.2. Synthesis of [(p6-p-cymene)Ru(Ln)Cl] (3–6)
(n=3–6)
Complexes 3–6 were synthesized by a general proce-
dure in which a 0.33 mmol (200 mg) of [(h6-p-
cymene)RuCl2]2 was treated with 0.70 mmol of the
ligand HLn in the presence of 0.83 mmol (90 mg) of
Na2CO3 under continuous stirring for 4 h in 15 ml
CH2Cl2 at 25 °C. The solid product thus obtained was
thoroughly washed with n-hexane and dried under vac-
uum (yield: ꢀ90%). Dark-red crystals of 5·MeCN were
obtained on cooling a solution of the complex in a
mixture of Me2CO, petroleum ether and MeCN at
−10 °C.
4.1. Synthesis of [(p6-p-cymene)Ru(Ln)Cl] (n=1, 2)
from oxygen-insertion reactions (1, 2)
The complexes 1 and 2 were prepared by reacting
0.21 mmol of [(h6-p-cymene)Ru(L%)Cl], where L% is
monoanionic, C,N-donor (phenylazo)-phenyl or 4,4%-
dimethyl(phenylazo)phenyl, with 0.31 mmol (54 mg) of
m-chloroperbenzoic acid under refluxing condition in a
10 ml solution of CHCl3 and MeOH (1:1, v/v) for 6 h.
After cooling the reaction mixture to an ambient tem-
perature, it was filtered through celite, reduced to a
volume of ꢀ3 ml and subjected to column chromatog-
raphy using neutral alumina, deactivated with MeOH
prior to use. Elution with a mixture of MeOH and
CHCl3 (1:20, v/v) gave the product as a reddish band,
which was separated and dried under vacuum (yield:
ꢀ20%).
Anal. Found: C, 57.20; H, 4.85; N, 6.21. Calc. for
C22H23N2OClRu (1): C, 56.46; H, 4.90; N, 5.99%. Visi-
ble spectral data: umax (nm) (m, l mol−1 cm−1) (MeCN):
330 (23 990), 456 (12 760), 551 (6040). 1H-NMR
(CDCl3, 200 MHz, l ppm): 0.68, 0.86 (2d, 2×3H,
[3JHH=8 Hz], CHMe2), 2.18 (s, 3H, Me), 2.21 (sp,
[3JHH=7 Hz], CHMe2), 5.09, 5.38, 5.69, 5.77 (4d,
4×1H, [3JHH=6 Hz], four ring H) (p-cymene), 7.3 (m,
H4,5), 7.53 (m, H9–11), 8.12 (m, H8,12), 8.30 (m, H3), 8.50
(m, H6) (L1 ligand) (Hn, the hydrogen atom number
corresponding to the Cn given in Scheme 1, s, singlet; d,
doublet; m, multiplet; sp, septet). 13C-NMR (CH2Cl2,
200 MHz, l ppm): 18.87 (CHMe2), 21.12, 22.21
(CHMe2), 30.84 (Me), 85.9, 87.03, 92.59, 96.58, 102.2,
108.0 (ring C6H4) (p-cymene), 122.96, 124.60, 128.47,
129.92, 130.30, 130.50, 130.96, 133.58, 140.17 (C3–6,8–12),
157.0, 163.50 (C2,7), 168.85 (C1) (L1 ligand).
Anal. Found: C, 58.25; H, 5.40; N, 5.83. Calc for
C24H27N2ORuCl (2): C, 58.11; H, 5.45; N, 5.65%. Visi-
ble spectral data: umax (nm) (m, l mol−1 cm−1) (MeCN):
349 (21 570), 443 (13 010), 547 (6620). 1H-NMR
(CDCl3, 400 MHz, l ppm): 0.73, 0.88 (2d, 2×3H,
[3JHH=7 Hz], CHMe2), 2.10 (s, 3H, Me), 2.24 (sp,
[3JHH=7 Hz], CHMe2), 5.06, 5.14, 5.54, 5.64 (4d,
4×1H, [3JHH=6 Hz], four ring H) (p-cymene), 2.46 (s,
6H, C5ꢀMe, C10ꢀMe), 6.97 (d, [3JHH=7 Hz], H4), 7.27
(d, [3JHH=8 Hz], H8,12), 8.05 (m, H3,6,9,11) (L2 ligand).
13C-NMR (CDCl3, 400 MHz, l ppm): 19.70 (CHMe2),
21.12, 22.65 (CHMe2), 31.31 (Me), 85.76, 87.77, 92.36,
96.73, 103.42, 107.52 (ring C6H4) (p-cymene), 22.97,
24.49 (C5ꢀMe, C10ꢀMe), 123.35, 126.76, 129.47, 131.90,
Anal. Found: C, 57.51; H, 4.94; N, 5.89. Calc. for
C23H25N2OClRu (3): C, 57.32; H, 5.19; N, 5.82%. Visi-
ble spectral data: umax (nm) (m, l mol−1 cm−1) (MeCN):
316 (19 700), 398 (11 320), 562 (7980). 1H-NMR
(CDCl3, 400 MHz, l, ppm): 1.07, 1.14 (2d, 2×3H,
[3JHH=7 Hz], CHMe2), 2.19 (s, 3H, Me), 2.55 (sp,
[3JHH=7 Hz], CHMe2), 4.47, 4.93 (2d, 2×1H, [3JHH
=
6 Hz], ring H), 5.35 (s, 2H, ring H) (p-cymene), 2.21 (s,
3H, Me), 6.95, 7.09 (2d, 2×1H, [3JHH=9 Hz], H5,6),
7.37–7.48 (m, H5,9–11), 7.88 (m, H8,12) (L3 ligand).
13C-NMR (CDCl3, 400 MHz; l ppm): 19.21 (CHMe2),
20.34, 22.53 (CHMe2), 31.51 (Me), 81.34, 83.21, 86.14,
95.57, 99.97 (ring C6H4) (p-cymene), 30.95 (Me),
117.63, 121.53, 123.51, 124.34, 127.29, 128.27, 129.36,
136.32, 151.69 (C3–6,8–12), 156.73 (C2,7), 161.98 (C1) (L3
ligand).
Anal. Found: C, 56.80; H, 5.31; N, 5.49. Calc. for
C24H27N2O2ClRu (4): C, 56.30; H, 5.28; N, 5.47%.
Visible spectral data: umax (nm) (m, l mol−1 cm−1
)
(MeCN): 317 (17 310), 431 (13 440), 557 (6490). 1H-
NMR (CDCl3, 200 MHz, l ppm): 1.05, 1.11 (2d,
2×3H, [3JHH=8 Hz], CHMe2), 2.10 (s, 3H, Me), 2.63
(sp, [3JHH=7 Hz], CHMe2), 3.76, 4.91, 5.13, 5.53 (4d,
4×1H, [3JHH=6 Hz], four ring H) (p-cymene), 2.17 (s,
3H, Me), 4.03 (s, 3H, OMe), 6.86–7.17 (m, H5,9–11),
7.36–7.61 (m, H3,6,12) (L4 ligand). 13C-NMR (CDCl3,
400 MHz; l ppm): 18.92 (CHMe2), 20.19, 21.81
(CHMe2), 30.75 (Me), 80.77, 81.35, 82.50, 101.43,
103.07, 110.78 (ring C6H4) (p-cymene), 22.67 (Me),
56.02 (OMe), 117.72, 120.11, 121.09, 122.67, 125.64,
128.79, 136.03, 145.54 (C3–6,8–12), 147.54, 152.23 (C2,7),
172.23 (C1) (L4 ligand).
Anal. Found: C, 59.65; H, 4.91; N, 5.37. Calc. for
C26H25N2OClRu (5): C, 60.29; H, 4.83; N, 5.41%. Visi-
ble spectral data: umax (nm) (m, l mol−1 cm−1) (MeCN):
322 (15 400), 360 (15 010), 397 (11 820), 529 (10 200).
1H-NMR (CDCl3, 200 MHz, l ppm): 1.05, 1.12 (2d,
2×3H, [3JHH=7 Hz], CHMe2), 2.25 (s, 3H, Me), 2.51
(sp, [3JHH=7 Hz], CHMe2), 4.58, 4.96 (2d, 2×1H,